Skip NavigationSkip to Content
Return Return to Search Results

Twice-weekly pegylated interferon-alpha-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy

  1. Author:
    Murphy, A. A.
    Herrmann, E.
    Osinusi, A. O.
    Wu, L.
    Sachau, W.
    Lempicki, R. A.
    Yang, J.
    Chung, T. L.
    Wood, B. J.
    Haagmans, B. L.
    Kottilil, S.
    Polis, M. A.

  2. Author Address

    [Polis, MA] NIAID, Collaborat Clin Res Branch, LIR, NIH,DHHS, Bethesda, MD 20892 USA [Herrmann, E; Chung, TL] Goethe Univ Frankfurt, Dept Med, Inst Biostat & Math Modeling, Frankfurt, Germany [Wu, L] US FDA, Div Pulm Allergy & Rheumatol Prod, Silver Spring, MD USA [Osinusi, AO; Lempicki, RA; Yang, J] NCI, SAIC Frederick Inc, Frederick, MD 21701 USA [Wood, BJ] NIH, Div Radiol Radiol & Imaging Sci, Bethesda, MD 20892 USA [Haagmans, BL] Erasmus MC, Rotterdam, Netherlands;Polis, MA (reprint author), NIAID, Collaborat Clin Res Branch, LIR, NIH,DHHS, 6700B Rockledge Dr,1118, Bethesda, MD 20892 USA;mpolis@niaid.nih.gov
    1. Year: 2011
    2. Date: Jun
  2. Journal: Aids
    1. 25
    2. 9
    3. Pages: 1179-1187
  4. Type of Article: Article
  5. ISSN: 0269-9370
  1. Abstract:

    Background: Hepatitis C virus (HCV)/HIV co-infected patients have more rapid progression of liver fibrosis and only modest cure rates (sustained virologic responses, SVRs) when compared to HCV monoinfected patients. Method: We compared the virologic responses of either twice-weekly peginterferon-alpha-2a 180 mu g/week (for 4 weeks, followed by weekly dosing) or weekly peginterferon-alpha-2a 180 mu g/week, and weight-based ribavirin (1-1.2 g/day), among HIV/HCV co-infected genotype-1 individuals. Results: Patients receiving the investigational dosing had lower levels of HCV RNA at all time points after initiation of therapy. More patients on this arm achieved clinically relevant early virological responses at weeks 1, 2, 4, 12, and 24. The enhanced early virologic response observed with the investigational arm was associated with a higher induction of interferon-stimulated genes. This early double dose regimen also resulted in a rapid normalization of liver enzymes. Twice-weekly peginterferon-a-2a was associated with more frequent early virological responses with similar safety profiles when compared with standard therapy. Conclusion: Our results, when confirmed in larger randomized clinical trials, may provide a novel therapeutic approach to improve SVR among HIV/HCV co-infected patients, especially African-American patients. (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1097/QAD.0b013e3283471d53
  3. View record in Web of Science®
  4. WOS: 000290753700005

Library Notes

  1. Fiscal Year: FY2010-2011
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel